NeOnc Technologies Acquires AI and 3D Bioprinting IP, Appoints Dr. Ishwar K. Puri to Board.

NeOnc Technologies has closed a strategic acquisition of advanced AI and 3D bioprinting IP, strengthening its drug discovery engine and accelerating CNS cancer therapy development. The acquired IP allows for patient-derived 3D brain tumor models and high-throughput screening of therapeutic candidates with greater speed and accuracy. The deal was valued at $3.5 million and includes the appointment of Dr. Ishwar K. Puri to the Board of Directors.

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) has completed the acquisition of an intellectual property portfolio focused on AI, 3D bioprinting, and quantum modeling technologies for $3.5 million. The deal includes $500,000 in cash and $3 million in stock at $25 per share [1].

The acquired technology, which includes U.S. Patent No. 11,788,057 B2, enables the creation of sophisticated patient-derived 3D brain tumor models. By integrating AI and quantum modeling algorithms with realistic biological environments, NeOnc can now perform high-throughput screening of therapeutic candidates with greater speed and accuracy [1].

The acquisition addresses a critical bottleneck in CNS cancer drug development—the preclinical screening phase. Traditional methods often fail to predict how drugs will perform in actual brain tumors, leading to high failure rates in clinical trials. By implementing high-throughput screening with patient-derived tumor models, NeOnc can now more accurately identify promising drug candidates before advancing to expensive clinical testing [1].

The $3.5 million transaction structure preserves capital while demonstrating confidence in NeOnc's equity value. The technology will directly support NeOnc’s ongoing multi-Phase 2 clinical programs and its partnership with Quazar Investment Group in the GCC region [1].

Concurrent with the acquisition's closing, NeOnc welcomed Dr. Ishwar K. Puri to its Board of Directors. Dr. Puri is the Senior Vice President of Research and Innovation at the University of Southern California (USC) and is globally recognized as one of the top 0.4% of scholars by citation impact [1].

The acquisition creates multiple strategic advantages, including accelerated preclinical development, enhanced personalized medicine capabilities, reduced reliance on animal testing, and potential expansion beyond oncology into neurodegenerative diseases like Alzheimer's and Parkinson's [1].

References:
[1] https://www.stocktitan.net/news/NTHI/ne-onc-technologies-closes-strategic-acquisition-of-advanced-ai-and-h4xhsa30ytpg.html